• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio

    Frontage Bolsters Clinical Services Capabilities

    Sanofi Unveils EUROAPI as Name of New European API Company

    Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz

    Precision Medicine Group Acquires Project Farma
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Sanofi Unveils EUROAPI as Name of New European API Company

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza

    Fujifilm, CABIM Get $76M Funding for Mfg. and Innovation Center

    LSNE Expands Fill Finish and Lyophilization Ops
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe

    Schreiner MediPharm Joins DoseID Consortium
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Virtual Clinical Trials: The Future of Dermatology Studies

    Frontage Bolsters Clinical Services Capabilities

    Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

    CDMO Cognate BioServices Teams Up with L7 Informatics

    The Wasdell Group Earns ISO 13485 Certification
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Syngene

    Flow Sciences

    Adare Pharma Solutions

    Alcami

    Baxter BioPharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Adare Pharma Solutions

    PCI Pharma Services

    Emergent BioSolutions

    Baxter BioPharma Solutions

    Syngene
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    Orphan Drug Development & Production: Turning Lemons into Lemonade

    Forming a “win-win-win” paradigm for large pharma companies, contract service providers and generics

    Related CONTENT
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • Natoli Engineering Appoints Northeast Service Technician
    • COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge
    • Health Canada Authorizes Pfizer, BioNTech COVID-19 Vax
    • Health Canada Green Lights COVID-19 Vax
    Emil W. Ciurczak, DoraMaxx Consulting01.26.17
    Orphan drugs are not “orphans” for no reason. Much like buying a house that is listed as a fixer-upper, there is not much profit in making these entities; a lot of work may be needed to just break even. The obvious proof of that is, if they were money makers, Pfizer, GSK, or some other Big Pharma house would be selling them already. The cost of developing orphans in the traditional manner makes them prohibitively non-cost-effective. Under the traditional development paradigm (i.e., pre-formulation, formulation, scale-up, etc.), it could take years to produce an acceptable dosage form.

    The recipients/patients of the final orphan product almost always fall into two categories. The first is a small percentage of the population suffering from a rare ailment, such that, under the current blockbuster paradigm, Big Pharma cannot afford to develop and produce the product without incurring a loss.

    Next there is a large number of potential patients, but with limited ability to pay. This is the unfortunate state of a number of developing countries, normally in Africa, South/Central America, or Asia. A large number of people, living in Equatorial regions, fall prey to numerous tropical diseases (e.g., malaria), parasites, or other common diseases like typhus, polio, and typhoid, which have been controlled in developed countries. The per capita income of these people is such that they cannot afford medicines at a price that would allow a larger pharma company to realize a profit.

    The population crunch is a major problem. By that, I refer to the one-two punch of the limited patient population having a rare disease. With so few patients suffering from the rare disease, the ability to recover the costs of goods sold (COGS) and product development is very limited. The long development time and minimal production runs of a limited edition product could potentially cause the product to barely break-even or even a lose money, necessitating either an influx of government or charity monies to continue producing and distributing the product. All steps above require time, and time is money. Both product development and negotiations with government agencies or charities are quite labor-intensive for R&D and/or management personnel.

    Additionally, the pool of potential clinical trial patients could be extremely limited by the number of people suffering from a rare disease and, if the treatment is a one-time dose or one series of doses like gene therapy, for example, the patient pool of likely final product customers becomes even smaller when clinical trial patients are removed.

    With all the potential difficulties incurred with orphan drugs, there are still many companies engaged in making them. In addition to these forward-thinking smaller companies, many of the big boys are simultaneously outsourcing many of their operations. Of the outsourced functions, clinical trials make the most sense. These require a large number of office staff to do a competent job—QA, statisticians, etc. However, since there are fewer new chemical entities (NCEs) being tested for potential new drug applications (NDAs), the workload often does not justify the overhead of an in-house group, just for clinical trials. A contract research organization (CRO) can sustain the needed staff head-count by performing trials for several pharma companies at once.

    Then, there are the other functions of CROs and contract manufacturing organizations (CMOs). Besides merely producing a finished product for a larger client, they are now being utilized to do virtually all phases of drug development, production, analysis, packaging, distribution, and such. As the largest pharma companies outsource more and more functions, the contract companies need to become mini-clones of the parent companies. That means, if the client company embraces PAT, QbD, and continuous manufacturing (CM), they will need to obtain/build the proper hardware, software, and expertise. How does a smaller, less well-funded contract manufacturer manage to obtain the same toys as the innovators? There are a number of ways.

    “Find” the money
    I covered several possible routes companies can take to find the money to finance facilities in earlier columns. One was to enhance the lab function of your company by, for example, switching from commonly used HPLC to UPLC. The excess throughput/capacity would configure the analytical/QC lab to accept outside samples. The income from the new contract analysis lab may be used to finance newer process equipment and monitors, allowing the contract manufacturer to become capable of performing low impact formulation studies.

    By low impact, I mean using CN equipment to perform design of experiments for both clinical formulations and final product. CM equipment and continuous monitoring allows the formulator to use far smaller amounts of raw materials and APIs to develop the dosage form. In addition to saving materials, the time scale from beginning to final dosage form shrinks from weeks to one or two days.

    Pool resources
    There is also an opportunity for a number of smaller organizations to pool resources and develop a communal plant, either at one of their properties or a neutral site. The details would need to be worked out, as well as proprietary information protected, but, especially for companies making generics, there would be less emphasis on secrecy.

    The shared expenses would bring an already less expensive alternative to classic formulation and production to lower levels by assuring that the equipment would only be used as needed, lowering the yearly ownership costs.

    Another benefit could be co-education of several members of each firm, rather than having to support a huge staff for each company. Mutual non-disclosure agreements could protect each company’s interests, yet allowing the staffs to work together.

    Clients take charge
    The third way is for larger companies (clients) to simply install CM units at CRO/CMO facilities. For a year or two, Pfizer has been showing their modular CM units. These are analogous to pre-fabricated houses, where the several pieces are fabricated at a central location, tested for functionality, and then transported to a remote site. The remote sites for Pfizer, so far, have been their own properties, not already equipped with such equipment.

    The stated purpose was to assure that the products generated at the remote site were nearly identical to the initiator site. This concept could easily be expanded to contract sites too. If the initiator company wishes to have a CMO pick up production, this approach would allow them to duplicate the initially submitted product with minimum revalidation. The other benefit is, when a blockbuster product either approaches or reaches its expiry date, the major company could continue producing it, under its own brand name, but at a greatly reduced price point and still make a profit greater than producing it in their own larger, higher overhead facility.

    You might ask why the larger pharma corporations would want potentially competitive CRO/CMOs to exist, much less pay for them to be so modern and cost-effective. There are several truths that they will recognize. First, when then initiator’s patent runs out, some, if not many, generics will absolutely produce the product and compete at a lower price.
    Second, insurance companies and, by extension, pharmaceutical companies, are coming under pressure from governmental agencies in multiple countries to lower costs. This will be extremely painful under current production paradigms.

    What a cooperation between large pharma, CRO/CMOs, and generics could accomplish would be a so-called “win-win-win” for the larger companies, smaller companies, and the contract companies. How could that work?
    1. Using a CMO from the beginning of a product’s lifecycle would, by avoiding the inherent overhead of the larger company, allow the cost of the drug to be more modest, yet allowing the originator to make a well-earned profit.
    2. This lower cost of production would allow the parent company to produce the product in the country in which it is being sold, allowing the local agency to oversee the facility and ensure a more robust supply chain. Add to that no need for importation inspections and savings on shipping costs, and the prices can be even more competitive.
    3. As the drug product comes off patent, the CMO with the mirror production lines could be incorporated to continue producing the drug under the initiator’s copyrighted name, but at a cost comparable with generic competition.
    4. If a generic or non-engaged CRO decides to produce a product coming off patent, the quality of that product could well rival the original, named product.
    So, point one is a win for the bottom line of an initiator company and the CMO involved; the former still makes money, while the latter employs trained production and lab staff. Point two is a win for the patients in the country where a product is produced: lower costs and assured quality are built in. Point three, the initiator can continue to carry brand recognition, make a profit, and, once again, employees of the CRO keep their positions. Point four is largely a win for the patients, who can use the generics, which are often insurance company mandated, with confidence.

    So, to summarize, the spread of PAT/QbD/CM capabilities is a win-win-win for large, initiator pharma companies, CRO/CMOs, and generics, and, not to be forgotten, the end user, for which the product was, after all, intended. Of course, similar arguments apply for large companies to follow this blueprint for research, development, and clinical trials.


    Emil W. Ciurczak
    DoraMaxx Consulting

    Emil W. Ciurczak has worked in the pharmaceutical industry since 1970 for companies that include Ciba-Geigy, Sandoz, Berlex, Merck, and Purdue Pharma, where he specialized in performing method development on most types of analytical equipment. In 1983, he introduced NIR spectroscopy to pharmaceutical applications, and is generally credited as one of the first to use process analytical technologies (PAT) in drug manufacturing and development.
    Related Searches
    • Analytical Services
    • Laboratory Testing
    • Drug Development
    Suggested For You
    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021 The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    Natoli Engineering Appoints Northeast Service Technician Natoli Engineering Appoints Northeast Service Technician
    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge
    Health Canada Authorizes Pfizer, BioNTech COVID-19 Vax Health Canada Authorizes Pfizer, BioNTech COVID-19 Vax
    Health Canada Green Lights COVID-19 Vax Health Canada Green Lights COVID-19 Vax
    Frontida BioPharm Appoints Chief Financial Officer Frontida BioPharm Appoints Chief Financial Officer
    Pfizer, BioNTech Win First Authorization for COVID-19 Vax Pfizer, BioNTech Win First Authorization for COVID-19 Vax
    NeuBase Therapeutics Appoints Chief Scientific Officer NeuBase Therapeutics Appoints Chief Scientific Officer
    Pfizer, BioNTech Submit CMA for Covid-19 Vax to EMA Pfizer, BioNTech Submit CMA for Covid-19 Vax to EMA
    Life Science Success Podcast: Matt Hicks Life Science Success Podcast: Matt Hicks
    Pfizer and BioNTech to Submit EUA for COVID-19 Vaccine Pfizer and BioNTech to Submit EUA for COVID-19 Vaccine
    Delpharm to Manufacture Pfizer/BioNTech mRNA Vax in France Delpharm to Manufacture Pfizer/BioNTech mRNA Vax in France
    Pfizer, BioNTech Conclude Phase III COVID-19 Vax Study Pfizer, BioNTech Conclude Phase III COVID-19 Vax Study
    A Potential “Marriage” A Potential “Marriage”
    Bye-Bye China? Bye-Bye China?

    Related Columns

    • Analytical Services
      What Happens When the All-Clear Signal is Given?

      What Happens When the All-Clear Signal is Given?

      Maybe 3M had some good ideas?
      Emil W. Ciurczak, DoraMaxx Consulting 06.04.20

    • Analytical Services | Laboratory Testing
      The Supply Chain, as Developed by IKEA (some assembly required)

      The Supply Chain, as Developed by IKEA (some assembly required)

      Pick One from Column A, Two from Column B, etc.
      Emil W. Ciurczak, DoraMaxx Consulting 03.04.20

    • Analytical Services | Laboratory Testing
      Re-Open Your Tool Chest

      Re-Open Your Tool Chest

      There’s no longer an excuse NOT to start “PAT-ing” your products
      Emil W. Ciurczak, DoraMaxx Consulting 07.15.19


    • Biologics, Proteins, Vaccines | Drug Development
      The Future Is… Therapeutic

      The Future Is… Therapeutic

      As cell and gene therapies rise, so too does outsourcing
      Ben Locwin 06.13.19

    • Analytical Services | Laboratory Testing
      Solid Dose Manufacturing: It’s Time to Trade-in Your 1952 Studebaker

      Solid Dose Manufacturing: It’s Time to Trade-in Your 1952 Studebaker

      Making a solid case for PAT, QbD and continuous manufacturing in the pharma industry
      Emil W. Ciurczak, DoraMaxx Consulting 03.06.19

    • Analytical Services | Laboratory Testing
      The Great Diaspora of the Pharma Industry

      The Great Diaspora of the Pharma Industry

      Or, good things come in small(er) packages
      Emil W. Ciurczak, DoraMaxx Consulting 11.14.18


    • Analytical Services | Laboratory Testing
      Possibly Time for a New Paradigm

      Possibly Time for a New Paradigm

      Or, why the chicken should cross the road
      Emil W. Ciurczak, DoraMaxx Consulting 10.10.18

    • Analytical Services | Laboratory Testing
      The Times, They Are a-Changin’

      The Times, They Are a-Changin’

      For contract organizations and generics, for sure
      Emil W. Ciurczak, DoraMaxx Consulting 07.20.18

    • Analytical Services | Bioanalytical Services | Laboratory Testing
      The Final Frontier

      The Final Frontier

      A look at contract bioprocessing and PAT/QbD
      Emil W. Ciurczak, DoraMaxx Consulting 06.12.18


    • Analytical Services | Laboratory Testing
      We Need to Get Back to Basics

      We Need to Get Back to Basics

      In life, and the lab, the calculator/computer is a blessing and a curse!
      Emil W. Ciurczak, DoraMaxx Consulting 05.08.18

    • Chemistry | Laboratory Testing
      When Your Product is Neither a Liquid or a Solid

      When Your Product is Neither a Liquid or a Solid

      And you need to analyze/control it, in real time
      Emil W. Ciurczak, DoraMaxx Consulting 01.30.18

    • Analytical Services
      Finding the “Missing Link”

      Finding the “Missing Link”

      Outsourcing and the supply chain
      Emil W. Ciurczak, DoraMaxx Consulting 10.11.17


    • Drug Development | QA/QC | Regulatory Affairs
      India Frames Guidance for Drug Surveillance

      India Frames Guidance for Drug Surveillance

      Outsourcing PV functions to rise
      S. Harachand, Contributing Editor 07.18.17

    • Analytical Services | Laboratory Testing
      Analytical Equipment Technology for the 21st Century

      Analytical Equipment Technology for the 21st Century

      A look at some more toys available for CMOs, CROs and generics to boost their analytical capabilities
      Emil W. Ciurczak, DoraMaxx Consulting 05.09.17

    • Analytical Services
      Quality Risk Management

      Quality Risk Management

      It’s not just for the big guys anymore
      Emil W. Ciurczak, DoraMaxx Consulting 04.03.17

    Trending
    • Fujifilm To Invest $2B In US Manufacturing Site
    • Baxter, Novavax Ink Sterile Manufacturing Agreement
    • Catalent Acquires Acorda’s INBRIJA Manufacturing Operations
    • Precision Medicine Group Acquires Project Farma
    • A New Era Of Vaccine And Biologic Drug Development
    Breaking News
    • KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio
    • Frontage Bolsters Clinical Services Capabilities
    • Sanofi Unveils EUROAPI as Name of New European API Company
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • Precision Medicine Group Acquires Project Farma
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Brown Fat Associated with Reductions in Chronic Disease Risk
    NIH Study Identifies Antibacterial Properties in Taurine
    NSF Begins New Certification Program
    Coatings World

    Latest Breaking News From Coatings World

    Zeppelin Acquires MTI Mischtechnik
    Ezio Braggio Joins ChemQuest Europe
    IFS Coatings Announce Carbon Offset Program
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Optimize EP Launches CaRM Cardiac Device Data Management Platform
    U.S. TAVR Market Projected to Reach Nearly $5 Billion by 2030
    FDA Clears Canon Medical's Compressed SPEEDER for 3D Exams on 1.5T MR
    Contract Pharma

    Latest Breaking News From Contract Pharma

    KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio
    Frontage Bolsters Clinical Services Capabilities
    Sanofi Unveils EUROAPI as Name of New European API Company
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Neenah to Host Packaging Webinar for Printers
    W.S. Badger is Named a ‘150 Top Impact Company’
    Mana Products, Meiyume and RPG Form The Vertical Beauty Alliance
    Happi

    Latest Breaking News From Happi

    A Surge in Interest for Supplements & Vitamins
    What You're Reading on Happi.com
    Amyris Named a Top Social & Environmental Impact Company
    Ink World

    Latest Breaking News From Ink World

    dar-tech, inc. Becomes U.S. Midwestern Distributor for ZS Interpolymer
    Techkon USA, Konica Minolta Partner
    Alon Bar-Shany Appointed Chairman of Highcon Board
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Exhibitor registration opens for virtual.drupa
    FTA planning in-person Forum & INFOFLEX
    Fortis Solutions Group achieves SGP certification
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Shemesh Adds U.S. Headquarters
    TZMO USA, Special Needs Group Form Partnership
    BAHP Announces 2021 Officers, Board of Directors
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Rapid Recovery Protocol Can Lead to Increased Range of Motion After TKA
    Boston Scientific Releases WaveWriter Alpha Spinal Cord Stimulators in U.S.
    New Chief Clinical Officer on Board at IncludeHealth
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Roadsimple Modernizes Warehouse Ops with Zebra Technologies
    Toppan Announces 2050 Environmental Vision
    SOI Industry Consortium Joins SEMI as Strategic Association Partner

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login